Antipsychotic Drug Therapy

Historical comparison: drugs changed care previously involving institutionalisation; insulin shock & lobotomies
Cole (1964): 75% improved on conventional drugs vs 25% on placebo
Worsening; in the notes: none in the drug group vs 48% on placebo

Ravanic et al. (2009): five-year comparison
Atypicals such as clozapine: superior psychometric symptom scores & fewer adverse effects in the source
Qualification: conventional drugs can still help; response varies between individuals

Rettenbacher et al. (2004): 54.2% fully complied; 8.3% partly; 37.5% non-compliant
One possible barrier: patients may not believe they require medication
Practical implication: benefits depend partly on taking the agreed treatment

Clinical trial efficacy = benefit demonstrated under study conditions
Real-world effectiveness = benefit in ordinary care; with adherence & tolerability barriers
Judgement: evidence of efficacy does not guarantee equal everyday benefit

Efficacy = benefit demonstrated under study conditions. Effectiveness = benefit in ordinary care; where adherence & tolerability can limit outcomes.

1. In terms of effectiveness
Historical comparison: drugs changed care previously involving institutionalisation; insulin shock & lobotomies
Cole (1964): 75% improved on conventional drugs vs 25% on placebo
Worsening; in the notes: none in the drug group vs 48% on placebo
2. Comparing generations
Ravanic et al. (2009): five-year comparison
Atypicals such as clozapine: superior psychometric symptom scores & fewer adverse effects in the source
Qualification: conventional drugs can still help; response varies between individuals
3. However: non-compliance
Rettenbacher et al. (2004): 54.2% fully complied; 8.3% partly; 37.5% non-compliant
One possible barrier: patients may not believe they require medication
Practical implication: benefits depend partly on taking the agreed treatment
4. This creates a discrepancy
Clinical trial efficacy = benefit demonstrated under study conditions
Real-world effectiveness = benefit in ordinary care; with adherence & tolerability barriers
Judgement: evidence of efficacy does not guarantee equal everyday benefit
Precision note: Historical study figures are retained from your notes. Drug-specific results should not be generalised to every atypical or every patient.

Motor side effects: tardive dyskinesia & Parkinsonian effects
Other serious risks: agranulocytosis & seizures; risks differ between drugs
Ethical implication: weigh symptom relief against adverse effects

Acute psychotic episodes: may make understanding & decision-making difficult
Capacity to consent: requires individual assessment; not automatically absent
Concern: whether the person understands benefits; risks & alternatives

“Chemical straitjackets”: critics’ description of medication used to enforce conformity
Szasz (1960): criticised physical interventions & psychiatric labels
His argument: medical labelling can be used by society to manage non-conformity

Patient benefit: treatment intended to eliminate suffering?
Social compliance & control: or treatment used coercively to regulate behaviour?
Balanced judgement: evaluate consent & purpose without dismissing genuine clinical benefits

The person’s ability to understand the relevant benefits; risks & alternatives & make a decision. It requires individual assessment; schizophrenia does not automatically remove capacity.

1. Regarding: physical harm
Motor side effects: tardive dyskinesia & Parkinsonian effects
Other serious risks: agranulocytosis & seizures; risks differ between drugs
Ethical implication: weigh symptom relief against adverse effects
2. Informed consent
Acute psychotic episodes: may make understanding & decision-making difficult
Capacity to consent: requires individual assessment; not automatically absent
Concern: whether the person understands benefits; risks & alternatives
3. Furthermore: social control
“Chemical straitjackets”: critics’ description of medication used to enforce conformity
Szasz (1960): criticised physical interventions & psychiatric labels
His argument: medical labelling can be used by society to manage non-conformity
4. This prompts a dilemma
Patient benefit: treatment intended to eliminate suffering?
Social compliance & control: or treatment used coercively to regulate behaviour?
Balanced judgement: evaluate consent & purpose without dismissing genuine clinical benefits
Precision note: “Parkinsonianism” is corrected to Parkinsonian effects; the capacity-to-consent claim is qualified.

Delay & Deniker (1952): evaluation of chlorpromazine
Antipsychotics in the 1950s: contributed to reduced reliance on institutional care
Community-based care: greater opportunity for independent living

Reduced hospital reliance: may reduce the economic strain on hospitals
Independent living: depends on symptom control AND housing; follow-up & social support

Tiihonen et al. (2006): source cites ~37-fold suicide-risk association with non-use
NCISH (2015); source figures: 346 homicides; England; 2003-2013; 29% non-compliant before the offence
Interpretation: historical; selected-sample associations; not general predictions

Association ≠ causation: other differences may influence medication use & outcomes
Avoid denominator errors: a figure among offenders is not the violence risk of all patients
Overall judgement: continuity of care matters; social implications require contextual evidence

Confusing a percentage within a selected offender sample with the risk of violence among all people with schizophrenia. These are different populations & different probabilities.

1. Positively: changed care
Delay & Deniker (1952): evaluation of chlorpromazine
Antipsychotics in the 1950s: contributed to reduced reliance on institutional care
Community-based care: greater opportunity for independent living
2. Economic & practical benefits
Reduced hospital reliance: may reduce the economic strain on hospitals
Independent living: depends on symptom control AND housing; follow-up & social support
3. Conversely: adverse outcomes
Tiihonen et al. (2006): source cites ~37-fold suicide-risk association with non-use
NCISH (2015); source figures: 346 homicides; England; 2003-2013; 29% non-compliant before the offence
Interpretation: historical; selected-sample associations; not general predictions
4. Therefore: interpret carefully
Association ≠ causation: other differences may influence medication use & outcomes
Avoid denominator errors: a figure among offenders is not the violence risk of all patients
Overall judgement: continuity of care matters; social implications require contextual evidence
Precision note: non-use associations do not prove that stopping medication caused an outcome. These historical figures are retained only with their limits.